A new product was developed as potential multi-mycotoxin adsorbent. This product was evaluated in vitro at different pH values simulating those encountered in the GI tract of animals. Then, the efficacy of the additive in adsorbing mycotoxins was confirmed in vivo in short-term toxicokinetic studies with rats and piglets. Mycotoxins, with or without the detoxifier, were administered by a single oral intragastric bolus and their metabolites were determined in urine of rats and plasma of piglets. The reduction of mycotoxins and metabolites in urine and plasma confirmed that a reduction of mycotoxins systemic exposure occurred in presence of the additive.
Addressing target audiences and expressing needs
- Expanding to more markets /finding new customers
- Use of research Infrastructure
- Collaboration
We are looking for key opinions leaders to enhance our marketing strategy and communication to customers.
- Other Actors who can help us fulfil our market potential
- Research and Technology Organisations
R&D, Technology and Innovation aspects
Production of the new feed additive for multi-mycotoxin adsorption is being optimized at pilot scale. In vivo trials are ongoing to confirm dosage and way of use. Next step is the scale-up at industrial level, EFSA evaluation for efficacy and safety, and then market launch.
The use of the feed additive can be replicated in different animals, monogastrics and ruminants, to help to reduce and prevent toxic effects ot mycotoxins. Depending on the mycotoxin contamination and the specie, adjustments on the additive dosage can be made.
